Patent Examiner Sudhakar Katakam
Art Unit 1658 · Peptide & Protein Therapeutics · Tech Center 1600 · 336 applications filed 2021–2026
Sudhakar Katakam is a USPTO patent examiner in Art Unit 1658 (Peptide & Protein Therapeutics) with 336 applications from filing years 2021–2026. Examiner Katakam's allowance rate is 69.5%, below the 81.9% USPTO average for applications filed in the same years. The examiner ranks harder than 74% of examiners. In 2021, decided applications with an examiner interview were allowed 62.5 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1658 · Peptide & Protein Therapeutics
- Title / gradePrimary Patent Examiner · GS-14
- Service20 years
- PhoneOn each office action
- Email[email protected]
- In USPTO recordsKATAKAM, SUDHAKAR
Examiner Katakam can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Katakam
- The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 39.7 to 66.7 points.
- Plan for the timeline. First office action averages 748 days vs the 631-day USPTO norm.
- Expect a §103. Obviousness is the most-issued rejection (191), and applicants overcame it 53.6% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 21.8 to 43.3 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeOf the 42 winning responses to Examiner Katakam's §103 rejections that Boundly has classified, 35 (83%) amended the claims and argued, 4 argued without amending, and 3 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Katakam?
Draft your response with Examiner Katakam's record and Art Unit 1658's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response workflow.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2023 | 23.1% | 93.3% | 53.6% | +39.7pp |
| 2022 | 38.2% | 100.0% | 33.3% | +66.7pp |
| 2021 | 62.7% | 93.8% | 31.3% | +62.5pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Katakam.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2023 | 12.1% | 85.7% | 63.9% | +21.8pp |
| 2022 | 31.6% | 93.3% | 50.0% | +43.3pp |
| 2021 | 40.9% | 91.4% | 62.3% | +29.1pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/244800 | Therapeutic Agents for Treatment of Coronavirus Infection | Abandoned | 0 | 🔒 View |
| 18/015927 | Novel Peptoid Compounds That Bind to Cell Receptor ACE2 and Prevent Virus Entry into Cells | Patented | 1 | 🔒 View |
| 19/329353 | Cyclic Cell Penetrating Peptides and Methods of Making and Using Thereof | Patented | 1 | 🔒 View |
| 18/451003 | Polypeptides Including a Beta-Tricalcium Phosphate-Binding Sequence and Uses Thereof | Patented | 1 | 🔒 View |
Art Unit 1658 technology
Frequently asked questions
What is Examiner Sudhakar Katakam's allowance rate?
Is Examiner Katakam a hard examiner?
Do examiner interviews help with Examiner Katakam?
What is Examiner Katakam's most common rejection?
Is an RCE worth filing with Examiner Katakam?
How long until the first office action from Examiner Katakam?
How do I contact Examiner Sudhakar Katakam?
Put Examiner Katakam's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.